Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 13, 2016 2:23 AM ET


Company Overview of H3 Biomedicine Inc.

Company Overview

H3 Biomedicine Inc., a biopharmaceutical company, is engaged in the discovery and development of small-molecule drugs to treat cancer. H3 Biomedicine Inc. has a strategic collaboration with Selvita S.A. The company was founded in 2010 and is based in Cambridge, Massachusetts. H3 Biomedicine Inc. operates as a subsidiary of Eisai Inc.

300 Technology Square

Fifth Floor

Cambridge, MA 02139

United States

Founded in 2010



Key Executives for H3 Biomedicine Inc.

President and Chief Executive Officer
Scientific Founder
Age: 59
Scientific Founder
Senior Vice President of Planning and Operations
Associate Director of Business Development
Compensation as of Fiscal Year 2015.

H3 Biomedicine Inc. Key Developments

H3 Biomedicine and Selvita Extend Precision Cancer Medicines Collaboration

H3 Biomedicine Inc. and Selvita announced that they have extended their strategic collaboration to develop breakthrough precision medicines for cancers through September 2016. As part of the original collaboration begun in September 2013, the companies are validating the druggability of two kinase targets in a specific genetic context and have generated multiple novel chemical series against these targets. The companies are seeking to make further progress towards the initiation of IND enabling studies during 2016. The results from both programs will be presented at scientific conferences in the first half of 2016. The agreement calls for H3 Biomedicine to provide additional research funding to Selvita, in addition to milestones and royalties on both programs. The financial terms of the agreement are confidential.

H3 Biomedicine Inc. Presents at Boston Biotech BD Boston Conference, Mar-26-2014 04:00 PM

H3 Biomedicine Inc. Presents at Boston Biotech BD Boston Conference, Mar-26-2014 04:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Markus Warmuth, President and Chief Executive Officer.

Similar Private Companies By Industry

Company Name Region
VivaCeuticals, Inc. United States
Velocity Pharmaceutical Development, LLC United States
Sopherion Therapeutics, LLC United States
NanoVec, Inc. United States
VSL Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact H3 Biomedicine Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at